Abstract
Major depressive disorder is a common mental disease with unknown aetiology. Recent pre-clinical and clinical studies have suggested that the receptor tropomyosin related kinase B (TrkB) and its ligand, brain derived neurotrophic factor (BDNF), play essential roles in the pathogenesis and treatment of major depression. BDNF-TrkB pathway down-regulation may be the most important cause of major depression, while treatments that activate this pathway may improve depressive symptoms. Antidepressants, the main biological treatment for major depression, have been reported to increase central BDNF levels. However, a substantial proportion of depressed patients do not improve clinically despite appropriate antidepressant treatment and, in rare cases, antidepressants can induce or increase suicidal tendencies. In this report, several possible mechanisms relating to BDNF-TrkB signaling are proposed to account for these adverse effects of antidepressants. In addition, several strategies that may increase BDNF-TrkB signaling are proposed for the improved treatment of major depression.
Keywords: Major depressive disorder, receptor tropomyosin related kinase B, brain derived neurotrophic factor, antidepressant, p75 neurotrophin receptor
Current Signal Transduction Therapy
Title: A Clinical View of BDNF-TrkB Signaling in the Treatment of Major Depression
Volume: 2 Issue: 3
Author(s): Shih-Jen Tsai
Affiliation:
Keywords: Major depressive disorder, receptor tropomyosin related kinase B, brain derived neurotrophic factor, antidepressant, p75 neurotrophin receptor
Abstract: Major depressive disorder is a common mental disease with unknown aetiology. Recent pre-clinical and clinical studies have suggested that the receptor tropomyosin related kinase B (TrkB) and its ligand, brain derived neurotrophic factor (BDNF), play essential roles in the pathogenesis and treatment of major depression. BDNF-TrkB pathway down-regulation may be the most important cause of major depression, while treatments that activate this pathway may improve depressive symptoms. Antidepressants, the main biological treatment for major depression, have been reported to increase central BDNF levels. However, a substantial proportion of depressed patients do not improve clinically despite appropriate antidepressant treatment and, in rare cases, antidepressants can induce or increase suicidal tendencies. In this report, several possible mechanisms relating to BDNF-TrkB signaling are proposed to account for these adverse effects of antidepressants. In addition, several strategies that may increase BDNF-TrkB signaling are proposed for the improved treatment of major depression.
Export Options
About this article
Cite this article as:
Tsai Shih-Jen, A Clinical View of BDNF-TrkB Signaling in the Treatment of Major Depression, Current Signal Transduction Therapy 2007; 2 (3) . https://dx.doi.org/10.2174/157436207781745319
DOI https://dx.doi.org/10.2174/157436207781745319 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences
Current Pharmaceutical Design Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Oxidative RNA Damage and Neurodegeneration
Current Medicinal Chemistry Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Editorial (Thematic Issue: Molecular and Cellular Engineering Approaches for Neurological Disorders, Diseases, and Injuries Involved the Central and Peripheral Nervous Systems)
CNS & Neurological Disorders - Drug Targets The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Targeting ENaC as a Molecular Suspect in Cystic Fibrosis
Current Drug Targets Ceftriaxone and Phenylalanine Combination as Broad Spectrum Antimicrobials Therapy
Current Drug Therapy Frontier View on Nanotechnological Strategies for Neuro-therapy
Current Drug Metabolism Gene Therapy in Peripheral Nerve Reconstruction Approaches
Current Gene Therapy Editorial: Advances in Alzheimer Therapy: Something Old, Something New, Something Borrowed, Something Blue
Current Alzheimer Research Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Ligands Targeting the Excitatory Amino Acid Transporters (EAATs)
Current Topics in Medicinal Chemistry Cyclin-Dependent Kinase Inhibitors: Cancer Killers to Neuronal Guardians
Current Medicinal Chemistry Nano Clinoptilolite: Highly Efficient Catalyst for the Synthesis of Chromene Derivatives Under Solvent-Free Conditions
Combinatorial Chemistry & High Throughput Screening Role of Nuclear Factor Kappa B (NF-κB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach
Current Neuropharmacology Current Progresses of Novel Natural Products and Their Derivatives/ Analogs as Anti-Alzheimer Candidates: an Update
Mini-Reviews in Medicinal Chemistry Neurotransmitters and Microglial-Mediated Neuroinflammation
Current Protein & Peptide Science Targeting Neurotrophic/Growth Factor Expression and Signaling for Antidepressant Drug Development
CNS & Neurological Disorders - Drug Targets